Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00051324 · ClinicalTrials.gov registry record

Neurobiological Predictors of Huntington's Disease (PREDICT-HD)

A clinical trial of Huntington Disease, sponsored by Jordan Schultz.

Active
Registry status
1,700
Enrollment target
1
Study location

NCT00051324 is a study of Huntington Disease that is active but no longer recruiting, run by Jordan Schultz. The registered enrollment target is 1,700 participants, above the 587-participant average among 35 other Huntington Disease trials with a reported enrollment target (190% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00051324, a study of Huntington Disease, is active but no longer recruiting, sponsored by Jordan Schultz.

ACTIVE NOT RECRUITING
Registry status
1,700 participants
Enrollment target
1
Study location

Study Summary

The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms.

Conditions Studied

Study Locations (1)

Iowa

  • University of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 1,700 participants
Start Date 2002-08
Est. Completion 2025-06-30

Sponsor

Jordan Schultz

2 total trials

What the Registry Record Tells You About NCT00051324

The ClinicalTrials.gov registry entry for NCT00051324 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 587-participant average among 35 other Huntington Disease trials with a reported enrollment target (190% higher). The listed sponsor is Jordan Schultz, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 0 interventions.

NCT00051324 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.

Frequently Asked Questions

What is clinical trial NCT00051324 about?

NCT00051324 is a clinical study titled "Neurobiological Predictors of Huntington's Disease (PREDICT-HD)". The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms.

What is the current status of trial NCT00051324?

This trial is currently active not recruiting. The enrollment target is 1,700 participants. The study started on 2002-08. Estimated completion is 2025-06-30.

What conditions does trial NCT00051324 study?

This clinical trial studies the following conditions: Huntington Disease.

Who is sponsoring clinical trial NCT00051324?

This trial is sponsored by Jordan Schultz, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00051324 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Huntington Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.